NovaBridge Biosciences
NBP
15 insider filings · Latest: Sep 17, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Sep 21 8:05 PM | Phillip Andrew DennisChief Medical Officer | Sale | 8,209 | $0.71 | $5.8K | 173,427(D) | View → |
| Sep 18, 2026 | Sep 18 3:57 PM | Dennis Phillip Andrew | Proposed Sale | 3,569 | $1.62 | $5.8K | — | View → |
| Sep 9, 2026 | Sep 11 8:30 PM | Sean Wuxiong CaoChief Bus. Development Officer | Sale | 107,978 | $0.74 | $79.9K | 266,467(D) | View → |
| Sep 9, 2026 | Sep 9 6:48 PM | Cao Sean Wuxiong | Proposed Sale | 46,947 | $1.69 | $79.4K | — | View → |
| Aug 31, 2026 | Sep 1 10:00 PM | Cong Claire XuEVP, Clinical Development | Sale | 3,282 | $0.79 | $2.6K | 304,201(D) | View → |
| Jul 6, 2026 | Jul 7 11:50 PM | Cong Claire XuSVP, Clinical Development | Sale | 4,485 | $0.89 | $4.0K | 298,101(D) | View → |
| Jun 18, 2026 | Jun 22 9:23 PM | Phillip Andrew DennisChief Medical Officer | Sale | 8,494 | $0.66 | $5.6K | 157,941(D) | View → |
| Jun 1, 2026 | Jun 2 10:46 PM | Cong Claire XuSVP, Clinical Development | Sale | 3,494 | $3.94 | $13.8K | 290,154(D) | View → |
| May 14, 2026 | May 18 8:05 PM | Sean Wuxiong CaoDirector, Chief Business Development Officer and Director | Sale | 21,399 | $1.99 | $42.6K | 35,073(D) | View → |
| May 14, 2026 | May 14 6:50 PM | Cao Sean Wuxiong | Proposed Sale | 9,304 | $1.99 | $18.5K | — | View → |
| Apr 24, 2026 | Apr 28 8:05 PM | Mark Arnold HaglerPresident and Chief Commercial Officer | Purchase | 230,000 | $2.51 | $577.3K | 230,000(D) | View → |
| Mar 18, 2026 | Mar 18 8:08 PM | Dennis Phillip Andrew | Proposed Sale | 3,638 | $2.79 | $10.2K | — | View → |
| Jan 2, 2026 | Jan 2 9:00 PM | Skelton Joseph W. | Proposed Sale | 120,000 | $4.33 | $519.6K | — | View → |
| Dec 18, 2025 | Dec 18 4:30 PM | Dennis Phillip Andrew | Proposed Sale | 3,431 | $4.23 | $14.5K | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Sep 21 8:05 PM | Phillip Andrew DennisChief Medical Officer | Option Exercise | 10,302 | — | 72,120(D) | View → |
| Sep 3, 2026 | Sep 8 9:51 PM | Sean Wuxiong CaoChief Bus. Development Officer | Option Exercise | 147,553 | — | 135,960(D) | View → |
| Aug 30, 2026 | Sep 1 10:00 PM | Cong Claire XuEVP, Clinical Development | Option Exercise | 4,079 | — | 28,558(D) | View → |
| Aug 22, 2026 | Aug 25 8:15 PM | Robert A. LenzDirector | Option Exercise | 7,486 | — | 14,974(D) | View → |
| Jul 8, 2026 | Jul 10 9:00 PM | Mark Arnold HaglerChief Commercial Officer | Grant/Award | 949,050 | — | 949,050(D) | View → |
| Jul 8, 2026 | Jul 10 9:00 PM | Liwei Lorraine LinGeneral Counsel | Grant/Award | 254,780 | — | 254,780(D) | View → |
| Jul 6, 2026 | Jul 8 8:26 PM | Srishti GuptaDirector, Chief Executive Officer | Grant/Award | 3,000,000 | — | 3,000,000(D) | View → |
| Jul 4, 2026 | Jul 7 11:50 PM | Cong Claire XuSVP, Clinical Development | Option Exercise | 5,405 | — | 0(D) | View → |
| Jun 29, 2026 | Jun 30 8:15 PM | Wei FuDirector | Grant/Award | 3,910,680 | — | 1,010,100(D) | View → |
| Jun 22, 2026 | Jun 24 11:22 PM | Sean Wuxiong CaoDirector, Chief Bus. Development Officer | Grant/Award | 362,570 | — | 181,290(D) | View → |
| Jun 17, 2026 | Jun 22 9:23 PM | Phillip Andrew DennisChief Medical Officer | Option Exercise | 10,302 | — | 82,422(D) | View → |
| May 30, 2026 | Jun 2 10:46 PM | Cong Claire XuSVP, Clinical Development | Option Exercise | 4,079 | — | 32,637(D) | View → |